Engineering Turncoat Cancer Cells with CRISPR (1 of 1) (IMAGE)

American Association for the Advancement of Science (AAAS)

Engineering Turncoat Cancer Cells with CRISPR (1 of 1)

Caption

The CRISPR-engineered cancer cells (green) migrated towards an established glioblastoma tumor site (red) over the course of 28 days in a mouse model. This material relates to a paper that appeared in the 11 July, issue of Science Translational Medicine, published by AAAS. The paper, by C. Reinshagen at Brigham and Women's Hospital in Boston, MA; and colleagues was titled, 'CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors.'

Credit

C. Reinshagen <i>et al., Science Translational Medicine</i> (2018)

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.